Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $59.44 Average PT from Analysts

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in […]

Related Keywords

United States ,Canada ,Wellington ,New Zealand General ,New Zealand ,America ,Sherrington Robin ,Steven Gannon ,Needham Company ,Xenon Pharmaceuticals ,Xenon Pharmaceuticals Stock ,Timessquare Capital Management ,Nasdaq ,Institutional Investors Weigh In On Xenon Pharmaceuticals ,News Ratings For Xenon Pharmaceuticals Daily ,Citigroup ,Xenon Pharmaceuticals Inc ,Royal Bank ,Xenon Pharmaceuticals Company Profile ,Barclays Plc ,Analyst Recommendations For Xenon Pharmaceuticals ,Exchange Traded Concepts ,Wellington Management Group ,Walleye Capital ,Get Free Report ,Marketbeat Ratings ,Director Steven Gannon ,Management Group ,Square Capital Management ,Traded Concepts ,Get Free ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,Nasdaq Xene ,Exene ,Medical ,Ratings ,Consensus ,